Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T - PubMed
10 hours ago
- #B-ALL
- #CAR-NK cells
- #Immunotherapy
- Donor-derived CD19-targeted CAR-NK cells induced complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T therapy.
- CAR-NK cells show promise as a novel immunotherapy for pediatric relapsed/refractory B-ALL, with enhanced antitumor activity and low adverse event rates.
- The patient experienced grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), which was successfully managed with timely treatment.
- Following CAR-NK cell therapy, the patient underwent hematopoietic stem cell transplantation (HSCT) and remained in complete remission for a year post-HSCT.
- This case highlights CAR-NK cell therapy as a potential bridge to HSCT in pediatric R/R B-ALL, despite manageable toxicities like ICANS.